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Abstract
Background: Injection drug use is associated with an increased risk of human immunodeficiency virus (HIV) infection 
and with obstructive lung diseases (OLD). Understanding how HIV and OLD may impact respiratory symptoms among 
injection drug users (IDUs) is important to adequately care for this high-risk population. We characterized the 
independent and joint effects of HIV and OLD on respiratory symptoms of a cohort of inner-city IDUs.
Methods: Demographics, risk behavior and spirometric measurements were collected from a cross-sectional analysis 
of the Acquired Immunodeficiency Syndrome Link to the IntraVenous Experience study, an observational cohort of 
IDUs followed in Baltimore, MD since 1988. Participants completed a modified American Thoracic Society respiratory 
questionnaire and the Medical Research Council (MRC) dyspnea score to assess respiratory symptoms of cough, 
phlegm, wheezing and dyspnea.
Results: Of 974 participants, 835 (86%) were current smokers and 288 (29.6%) were HIV-infected. The prevalence of 
OLD (FEV1/FVC ≤ 0.70) was 15.5%, and did not differ by HIV status. OLD, but not HIV, was associated with increased 
frequency of reported respiratory symptoms. There was a combined effect of OLD and HIV on worsening of MRC 
scores. OLD and HIV were independently associated with an increased odds of reporting an MRC ≥ 2 (OR 1.83 [95%CI 
1.23-2.73] and 1.50 [95%CI 1.08-2.09], respectively). COPD, but not HIV, was independently associated with reporting an 
MRC ≥ 3 (OR 2.25 [95%CI 1.43-3.54] and 1.29 [95%CI 0.87-1.91], respectively).
Conclusions: While HIV does not worsen cough, phlegm or wheezing, HIV significantly increases moderate but not 
severe dyspnea in individuals of similar OLD status. Incorporating the MRC score into routine evaluation of IDUs at risk 
for OLD and HIV provides better assessment than cough, phlegm and wheezing alone.
Background
Injection drug use (IDU) is a prevalent social behavior in
urban centers that is associated with many acute and
chronic medical illnesses [1-4]. Due to similar underlying
risk factors in injection drug users (IDUs), unique chronic
medical conditions frequently co-exist in the same indi-
vidual [5-10]. IDU is a risk factor for the development of
two prevalent diseases: obstructive lung diseases (OLD),
specifically chronic obstructive pulmonary disease
(COPD) [11-13]. and human immunodeficiency virus
(HIV) infection[3,14,15]. In 2006, nearly 140,000 deaths
w e r e  a t t r i b u t e d  t o  e i t h e r  C O P D  o r  H I V  i n  t h e
States[16,17].
Risk factors for the development of OLD, such as
tobacco use and low socio-economic status, overlap in
those with HIV[18]. Prior studies have described the fre-
quent coexistence of HIV and OLD in at-risk popula-
tions[11,19,20]. Because IDUs are particularly vulnerable
to both OLD and HIV, it is important to explore how
these two diseases may impact respiratory status. To date,
no data exist on the impact of OLD and HIV on respira-
tory symptoms and functional status among and IDU
population. The Acquired Immunodeficiency Syndrome
(AIDS) Link to IntraVenous Experience (ALIVE)
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study[21]. has prospectively observed a cohort of both
HIV-infected and at risk IDUs in inner-city Baltimore,
Maryland, since 1988, providing an ideal dataset to exam-
ine the independent and joint effects of HIV and OLD on
manifestation of respiratory disease.
Methods
Setting and Participants
The methods for recruitment and data collection in the
ALIVE study have been previously described[21]. Sub-
jects were recruited through community outreach pro-
grams outside of treatment using distribution of flyers
and word of mouth. Briefly, participants were required to
be ≥ 18 yrs of age and have a history of injecting drugs.
ALIVE participants that underwent spirometry testing as
part of the lung sub-study were included in the current
analysis. This study was approved by Institutional Review
Boards of the Johns Hopkins Bloomberg School of Public
Health and the National Cancer Institute. All enrolled
participants provided written informed consent.
Data Collection
In this cross-sectional analysis, exposure and outcome
data were obtained from the ALIVE study visit where
spirometry was first obtained; participants also under-
went clinical examination, collection of blood specimens,
behavior and respiratory questionnaires. Smoking status
and duration, recent injection drug use and anti-retrovi-
ral or bronchodilator therapy were determined by self-
report. Medical conditions such as respiratory infections
or clinical AIDS events were identified through self-
report and confirmed through standardized medical
record abstraction. Spirometry was performed using a
KOKO® (Pulmonary Data Services, Inc., Louisville, CO)
pneumotach in accordance with American Thoracic
Society guidelines[22]. Percent predicted values were cal-
culated using standard formulas[23]. OLD was defined as
a pre-bronchodilator ratio of the forced expiratory vol-
ume in one second (FEV1) to forced vital capacity (FVC)
of ≤ 70%[24]. Participants completed a modified version
of the American Thoracic Society respiratory question-
naire[25]. Our questionnaire captured information
regarding presence, frequency and timing of respiratory
symptoms (cough, phlegm and wheezing). Dyspnea was
assessed using the modified Medical Research Council
(MRC) questionnaire with a validated 0-4 scale, with a
higher score indicating worse dyspnea[26,27]. The MRC
score has been shown to correlate with lung function and
long-term mortality in COPD patients and thus is
employed as a tool for assessment of disease impact [27-
29].
Statistical analysis
We compared the prevalence of respiratory symptoms in
individuals with and without OLD (defined by FEV1/FVC
≤ 70%) grouped by HIV status. Clinical and demographic
characteristics between groups were compared using t-
test for continuous variables. Categorical variables were
compared with Pearson's chi square and Fisher's exact
tests. Analysis of variance was performed to test the
effects of HIV and OLD on clinical and spirometric mea-
surements. Because of multiple comparisons, a Bonfer-
roni corrected p-value was used to assess for statistical
significance in the two-way comparison. Differences in
the distribution of MRC scores were assessed with Pear-
son's chi squared test. Multivariable logistic regression
models were generated to explore combinations of vari-
ables associated with different MRC thresholds. Covari-
ates were evaluated based upon known relevance from
clinical literature review and/or inspection of exploratory
data analysis. Odds ratios were adjusted for age, gender,
body-mass index (BMI), lifetime pack-years smoking,
number of lifetime pneumonias, presence of severe ane-
mia (hemoglobin<8 mg/dL) and injection drug use status.
Hemoglobin samples were not collected on HIV-unin-
fected participants prior to October 2007, thus these val-
ues were missing on 469 (48.2%) of the cohort. Results
with and without this covariate in logistic regression
modeling did not affect the overall results. Additional
multivariable models restricted to HIV-infected individu-
als compared thresholds of viral load and CD4 levels. All
data are presented as mean (standard deviation) for nor-
mally distributed data and median (interquartile range
[IQR]) for non-normally distributed data. Stata version
10.0 (Stata Corp, College Station, TX), was used for sta-
tistical analysis.
Results
Baseline Characteristics
Of the 1052 participants evaluated in the lung sub-study,
78 participants lacked complete spirometric data and
were excluded. Therefore, analysis presented includes
demographic, anthropometric, spirometric and respira-
tory questionnaire data from 974 individuals. Overall,
participants were a median age of 48.7 years old (IQR,
43.6-53.5 years), 65.9% were males, 89.8% were black.
Overall, 85.7% were current smokers, 9.3% were former
smokers and 4.9% had never smoked. A total of 288
(29.6%) individuals were HIV-infected. Of HIV-infected
participants, 155 (54.6%) reported highly active anti-ret-
roviral therapy (HAART) use in the last 6 months. HIV-
infected HAART users had a median CD4 count was 322
cells/mm3 (IQR, 177-503) and 109 (70.3%) had an unde-
tectable viral load. Of the 133 HIV-infected individuals
not reporting HAART use in the last 6 months, the
median CD4 count was 321 cells/mm3 (IQR, 178-497)
and 22 (16.5%) had an undetectable viral load. The preva-
lence of HIV infection among the 78 excluded partici-
pants (30.8%) was similar to those included in analysis
(29.6%).Drummond et al. BMC Pulmonary Medicine 2010, 10:27
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The prevalence of spirometry-defined OLD among par-
ticipants was 15.5%, which did not differ by HIV status
(HIV+ 15.6% vs. HIV-15.5%; p = 0.95). Study groups
formed by the presence or absence of OLD and HIV
included 580 participants negative for both diseases, 243
participants with HIV alone, 106 participants with OLD
alone and 45 participants with both OLD and HIV (Table
1). OLD+/HIV-participants were slightly older than the
other disease subgroups. Distribution of race differed
among the four disease strata. OLD-/HIV+ individuals
w e r e  m or e  li k e ly  t o be  bla c k w he n c om pa r ed t o t hose
with neither disease (OLD-/HIV-) (96.3 vs. 88.3%; p <
0.01) and both diseases (OLD+/HIV+) (96.3 vs. 86.7%; p
= 0.048). BMI also differed with HIV and COPD status.
Among HIV-participants, the presence of OLD was asso-
ciated with a lower BMI when compared to those without
COPD (p = 0.04). The presence of HIV was not associ-
ated with a difference in BMI among individuals of simi-
lar OLD status. As expected, bronchodilator use was
more common among patients with OLD regardless of
HIV status (OLD+/HIV-vs. OLD-/HIV-33.0 vs. 12.1%; p
< 0.01 and OLD+/HIV+ vs. OLD-/HIV+ 44.4 vs. 19.3%; p
< 0.01). In participants without OLD, bronchodilator use
was more frequently reported when HIV was present
compared to when HIV was absent (19.3% vs. 12.1%; p <
0.01).
Lung function
Among participants with OLD, those with HIV infection
had a lower absolute FEV1 and FVC compared to those
without HIV (1.97 L [0.73] vs. 2.36 L [0.84]; p = 0.019 and
3.17 L [1.01] vs. 3.69 L [1.17]; p = 0.014, respectively)
(Table 2). However, in those individuals with OLD, there
was no difference by HIV status in percent predicted
FEV1 (FEV1% predicted) (p = 0.05) and percent predicted
FVC (FVC% predicted) (p = 0.15).
Respiratory Symptoms
In individuals with neither OLD nor HIV, respiratory
symptoms were commonly reported, with 25.5% report-
ing cough, 29.5% reporting phlegm and 34.5% reporting
wheezing (Table 3). OLD, but not HIV, was associated
with more frequent respiratory symptoms. For HIV-par-
ticipants, those with OLD reported more frequent symp-
toms than those without OLD: cough 50.9% vs. 25.5% (p <
0.01), phlegm 49.1% vs. 29.5% (p < 0.01) and wheezing
61.3% vs. 34.5% (p < 0.01). Similarly, for HIV+ partici-
pants, those with OLD reported more frequent respira-
tory symptoms when compared to those without OLD:
cough 53.3% vs. 26.3% (p < 0.01), phlegm 60.0 vs. 31.3% (p
< 0.01) and wheezing 60.0 vs. 35.8% (p < 0.01). When
evaluating only HIV-infected subjects, neither HAART
use nor undetectable HIV RNA levels were associated
with differences in respiratory symptoms in individuals of
similar OLD status.
In order to assess the independent and joint effects of
HIV and OLD on dyspnea, we examined the distribution
of MRC scores by disease subgroup. Additionally, we
used logistic regression analysis to determine characteris-
tics associated with MRC score thresholds of ≥ 2 and ≥ 3.
These thresholds were chosen because of their known
correlation with significant impairment in functional sta-
tus (≥ 2)[30]. and with mortality (≥ 3)[28,31]. When strat-
ifying by OLD alone, the distribution of MRC scores was
worse for OLD+ individuals when compared to OLD-
individuals (p < 0.01) (Figure 1). When stratifying by HIV
s t a t u s  a l o n e ,  t h e  d i s t r i b u t i o n  o f  M R C  s c o r e s  t r e n d e d
towards worse scores for HIV+ individuals when com-
pared to HIV-individuals, although the test for trend did
not achieve statistical significance (p = 0.07) (Figure 2).
The distribution of MRC scores by each of the OLD/HIV
groups approximated an additive effect of HIV and OLD
(p < 0.01) (Figure 3). An MRC ≥ 2 was present in 151
(25.9%) of OLD-/HIV-individuals, 82 (33.1%) of OLD-/
HIV+ participants, 38 (35.8%) of OLD+/HIV-individuals
and 19 (42.2%) of OLD+/HIV+ participants (overall chi-
square p = 0.01). An MRC ≥ 3 was present in 87 (14.9%)
of OLD-/HIV-participants, 42 (16.9%) of OLD-/HIV+
participants, 24 (22.6%) of OLD+/HIV-participants and
15 (33.3%) of OLD+/HIV+ participants (overall p < 0.01).
Among HIV-infected individuals, neither CD4 cell
count<200, HAART use, nor undetectable HIV RNA lev-
els were associated with a difference in the distribution
and mean MRC scores in individuals of similar OLD sta-
tus.
After adjusting for demographic characteristics, smok-
ing intensity, current injection drug use and number of
pneumonias, logistic regression analysis demonstrated
that OLD was associated with an increased odds of
reporting an MRC ≥ 2 (OR 1.83; 95%CI 1.23-2.73; p <
0.01) and an MRC ≥ 3 (OR 2.25; 95%CI 1.43-3.54; p <
0.01) (Table 4). HIV infection was associated with an
increased odds of reporting an MRC ≥ 2 (OR 1.50; 95%CI
1.08-2.09; p = 0.02) but this association was attenuated
for an MRC ≥ 3 (OR 1.29; 95%CI 0.87-1.91; p = 0.20).
Female gender, higher BMI and higher lifetime pack-
years smoking were associated with an increase in the
odds of reporting an MRC ≥ 2 and ≥ 3 in all models. In
HIV-infected subjects, adjusting for HIV severity (viral
load>200,000 copies/mL versus viral load ≤ 200,000 cop-
ies/mL or CD4>200 vs. CD4 ≤ 200), did not attenuate the
effect of OLD on dyspnea.
Discussion
I n  t h i s  r e p o r t ,  w e  h a v e  c h a r a c t e r i z e d  t h e  r e s p i r a t o r y
symptoms of a large cohort of IDUs at-risk for HIV andDrummond et al. BMC Pulmonary Medicine 2010, 10:27
http://www.biomedcentral.com/1471-2466/10/27
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Table 1: Clinical and demographic characteristics of study participants.
OLD- OLD+
HIV- HIV+ HIV- HIV+ P-value*
N 580 243 106 45
Age, yr 48.1 (8.04) 47.7 (6.44) 50.1 (8.82) 48.8 (8.40) 0.05
Male, n(%) 385 (66.4) 152 (62.6) 75 (70.8) 30 (66.7) 0.49
Race/ethnicity, n(%)
Black 512 (88.3) 234 (96.3) 90 (84.9) 39 (86.7) <0.01
Smoking status, n(%)
Current 500 (86.2) 203 (83.5) 94 (88.7) 38 (84.4)
Former 53 (9.14) 25 (10.3) 10 (9.43) 3 (6.67)
Never 27 (4.66) 15 (6.17) 2 (1.89) 4 (8.89) 0.53
Smoking, pack-yr 19.5
(12-33)
19
(10.5-32.4)
20.8
(14-36)
21.9
(10.8-36.5)
0.56
Current IDU, n(%) 246 (42.4) 87 (35.8) 44 (41.5) 15 (33.3) 0.25
6 mo income, n(%)
Not reported 12 (2.1) 7 (2.9) 5 (4.7) 2 (4.4)
None 147 (25.3) 52 (21.4) 21(19.8) 7 (15.6)
<$5,000 274 (47.2) 133 (54.7) 51 (48.1) 25 (55.6)
$5,000-$10,000 91 (15.7) 39 (16.0) 23 (21.7) 6 (13.3)
>$10,000 56 (9.7) 12 (4.9) 6 (5.7) 5 (11.1) 0.13
High school education, 
n(%)
259 (44.7) 85 (35.0) 42 (39.6) 18 (45) 0.10
BMI, (kg/m2)2 5 . 7
(22.8-30.3)
24.9
(21.8-29.1)
24.2
(22.0-27.6)
22.3
(21.2-28.3)
<0.01
Hemoglobin (gm/dL) 13.4 (1.61) 12.8 (1.58) 13.4 (1.82) 12.9 (1.91) <0.01
MRC score 0.96 (1.25) 1.19 (1.31) 1.35 (1.41) 1.69 (1.46) <0.01
Bronchodilator use, n(%) 70 (12.1) 47 (19.3) 35 (33.0) 20 (44.4) <0.01
CD4 cell count N/A 323
(177-502)
N/A 305
(168-487)
0.88
HIV viral load
>400 copies, n(%) N/A 112 (46.1) N/A 19 (42.2) 0.63
X 100K, mean(SD)± 62.2 (103) 111 (176) 0.06Drummond et al. BMC Pulmonary Medicine 2010, 10:27
http://www.biomedcentral.com/1471-2466/10/27
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OLD. This analysis has yielded several important find-
ings. First, in this population with almost ubiquitous ciga-
rette smoking, we identified a high prevalence of
respiratory symptoms even in the absence of OLD and
HIV. While there was not an increased prevalence of
reported cough, phlegm and wheezing associated with
HIV, we did find that when HIV infection and OLD coex-
isted, dyspnea was worse than when either disease was
present alone. Furthermore, HIV was independently
associated with moderate dyspnea after controlling for
the presence of OLD and other confounders.
Within this IDU cohort, a high prevalence of respira-
tory symptoms was present even in those participants
without OLD or HIV. Despite the mean age of 48.7 years
in our study cohort, the rates of respiratory symptoms
observed in those without OLD and HIV are similar to
rates reported in a population of elderly Medicare smok-
ers[32]. A prior report of 234 HIV-infected individuals, of
whom 6.8% had spirometry-defined COPD, described a
similar frequency of respiratory symptoms[33]. Our
report highlights the significant symptom burden experi-
enced by the IDU population with heavy tobacco habits.
We extend prior publications by stratifying respiratory
symptoms and functional status in a population of injec-
tion drug users by OLD and HIV status. Prior publica-
tions have been limited to descriptions of respiratory
symptoms in either OLD or HIV, but not in both disease
states[34,35].
While HIV status was not associated with increasing
cough, phlegm and wheezing, there was a combined
effect of HIV and OLD on dyspnea assessed by the MRC
scale. To our knowledge, no prior study has evaluated the
effect of HIV on MRC scores in individuals with and
without OLD. Our analysis has shown that the presence
of HIV is associated with a detrimental shift in the distri-
bution of MRC scores when OLD is present, and this
effect was independent of HIV severity. Moreover,
patients who had both OLD and HIV had the highest
proportion of MRC scores ≥ 2 and ≥ 3. Female gender was
associated with increased odds of reporting an MRC ≥ 2
and ≥ 3 after adjusting for other characteristics. These
findings add information to prior publications examining
respiratory symptoms in HIV-infected populations,[11]
which have not included female participants. We
observed a >50% increase in the risk of reporting an MRC
≥ 2 in the presence of HIV, highlighting the impact of
HAART use, n(%) N/A 133 (54.7) N/A 22 (48.9) 0.19
Pneumonia, n(%)
All 15 (2.59) 3 (1.23) 3 (2.83) 1 (2.22) 0.57
Pneumocystis 0 2 (0.82) 0 0 0.22
*P-value represents test for overall difference across means or proportions. Values presented as mean (S.D.) or median (IQR) unless indicated. 
OLD = Obstructive lung disease; HIV = Human immunodeficiency virus; IDU = Injection drug use; BMI = Body mass index; MRC = Medical 
research council; CD4 = CD4+ T-Helper cells; HAART = Highly active anti-retroviral therapy; pack-yr = Number of packs smoked per day * years 
smoked; ±Mean(SD) of viral load only for those participants with viral load >400.
Table 1: Clinical and demographic characteristics of study participants. (Continued)
Table 2: Spirometry characteristics of study participants.
OLD- OLD+
HIV- HIV+ HIV- HIV+ P-value*
FEV1/FVC 79.2 (4.83) 79.8 (5.44) 63.4 (6.75) 61.2 (7.95) <0.01
FEV1
Absolute (L) 2.93 (0.75) 2.80 (0.66) 2.36 (0.84) 1.97 (0.73) <0.01
% Predicted 95.9 (15.3) 95.0 (15.2) 73.8 (18.2) 66.4 (19.7) <0.01
FVC
Absolute (L) 3.71 (0.96) 3.53 (0.86) 3.69 (1.17) 3.17 (1.01) <0.01
% Predicted 97.5 (15.8) 96.2 (15.8) 92.3 (18.9) 86.1 (20.5) <0.01
*P-value represents test for overall difference across means. Values presented as mean (S.D.) OLD = Obstructive lung disease; HIV = human 
immunodeficiency virus; FEV1 = Forced expiratory volume in 1 sec; FVC = Forced vital capacity;Drummond et al. BMC Pulmonary Medicine 2010, 10:27
http://www.biomedcentral.com/1471-2466/10/27
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HIV infection on dyspnea of individuals without substan-
tially altering cough, phlegm and wheezing. Interestingly,
OLD, but not HIV, remained an important predictor of
reporting an MRC ≥ 3, suggesting that HIV may increase
mild impairment independent of OLD, but advanced dys-
pnea is largely driven by OLD.
Several potential mechanisms exist by which HIV
infection may increase the susceptibility to respiratory
symptoms and diseases. HIV-infected individuals dem-
Table 3: Prevalence of respiratory symptoms stratified by OLD and HIV status.
OLD- OLD+
HIV- HIV+ HIV- HIV+
N 580 243 106 45
Cough, n(%)
Present 148 (25.5) 64 (26.3) 54 (50.9) 24 (53.3)
Morning cough 93 (16.0) 38 (15.6) 35 (33.0) 17 (37.8)
≥ 4 days/week 109 (18.8) 46 (18.9) 37 (34.9) 23 (51.1)
≥ 3 months 61 (10.5) 31 (12.8) 22 (20.8) 11 (24.4)
Phlegm, n(%)
Present 171 (29.5) 76 (31.3) 52 (49.1) 27 (60.0)
Morning phlegm 101 (17.4) 44 (18.1) 39 (36.8) 18 (40.0)
≥ 4 days/week 109 (18.8) 54 (22.2) 37 (34.9) 21 (46.7)
≥ 3 months 78 (13.5) 30 (12.4) 24 (22.6) 13 (28.9)
Wheezing, n(%)
Ever 200 (34.5) 87 (35.8) 65 (61.3) 27 (60.0)
Most days and 
nights
61 (10.5) 31 (12.8) 30 (28.3) 15 (33.3)
History of wheezing 
attack
117 (20.2) 54 (22.2) 47 (44.3) 21 (46.7)
Values presented as n(%). OLD = Obstructive lung disease; HIV = human immunodeficiency virus
Figure 1 Distribution of MRC scores by disease status. The distri-
bution of MRC scores by OLD status alone (OLD = Obstructive lung dis-
ease; MRC = Medical research council). P-values represent overall chi-
squared test.
Figure 3 Distribution of MRC scores by disease status. The distri-
bution of MRC scores by combined OLD and HIV states. (OLD = Ob-
structive lung disease; HIV = Human immunodeficiency virus; MRC = 
Medical research council). P-values represent overall chi-squared test.Drummond et al. BMC Pulmonary Medicine 2010, 10:27
http://www.biomedcentral.com/1471-2466/10/27
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onstrate elevated systemic inflammatory cytokines,
including those implicated in the pathogenesis of OLD
[36-38]. Moreover, elevated inflammatory cytokines are
observed in the bronchoalveolar lavage fluid of asymp-
tomatic HIV-infected individuals[39]. In lung autopsy
specimens of HIV-infected individuals, areas of histologi-
cal emphysema had many HIV-1 infected cells, whereas
rare HIV-1 infected cells were evident in normal lung,
suggesting that direct HIV infection may drive emphy-
sema formation[40]. These observations suggest that
infection with HIV leads to systemic and local abnormali-
ties that may promote the development of OLD. Addi-
tionally, HIV infection is associated with an increase in
the development of pulmonary arterial hypertension,[41]
which may be independently associated with increased
respiratory symptoms.
Our study has several implications for health care pro-
viders caring for IDU patients at risk for OLD and HIV.
The high prevalence of smoking and respiratory symp-
toms identifies IDUs as patients who would benefit from
aggressive smoking cessation and spirometry screening
initiatives. Second, when assessing respiratory symptoms
in HIV+ patients at-risk for OLD, providers should be
hesitant to attribute reported respiratory symptoms
solely to HIV infection. Rather, healthcare providers
should be vigilant to screen for undiagnosed OLD in this
population. Third, clinicians should consider incorporat-
ing dyspnea as well as cough, phlegm and wheezing into
routine assessments. Given that MRC scores have been
shown to correlate with morbidity and mortality in longi-
tudinal studies of OLD patients,[28,31] incorporation of
the MRC scale into routine clinical assessments of IDUs
may provide further risk stratification of populations with
the combined co-morbidities of OLD and HIV.
Our study has some limitations. First, the cross-sec-
tional nature of this analysis prevents conclusions regard-
ing longitudinal outcomes such as rate of FEV1 decline
and mortality. Although analyses incorporating markers
of advance HIV did not attenuate the effect of OLD on
respiratory symptoms, the high background prevalence
of smoking and respiratory symptoms in our population
may be obscuring any effect of advanced HIV on respira-
tory illness. IDUs participating in longitudinal observa-
tional studies may differ from the general IDU
population, impacting generalizability. Moreover, the
inner-city characteristics of this cohort may further limit
the generalizability of our findings to other IDU popula-
tion or different populations with OLD and HIV. The
absence of pre- and post-bronchodilator testing in this
cohort does not allow us to make conclusions regarding
the different symptom profile of asthma and COPD.
While we accounted for number of pneumonias in our
analysis, prior studies have reported that IDUs have an
increased risk of bacterial pneumonia and tuberculosis
Figure 2 Distribution of MRC scores by disease status. The distri-
bution of MRC scores by HIV status alone. (HIV = Human immunodefi-
ciency virus; MRC = Medical research council). P-values represent 
overall chi-squared test.
Table 4: Adjusted odds ratio (95%CI) of MRC thresholds*.
MRC ≥ 2 MRC ≥ 3
OLD 1.83 (1.23-2.73) 2.25 (1.43-3.54)
HIV 1.50 (1.08-2.09) 1.29 (0.87-1.91)
Female 3.86 (2.81-5.30) 4.38 (2.99-6.42)
BMI (per kg/m2) 1.06 (1.03-1.08) 1.05 (1.02-1.07)
Smoking (per 10-pk yrs) 1.24 (1.13-1.36) 1.22 (1.09-1.36)
*Adjusted for other variables in the table as well as age, current injection drug use status and number of pneumonias. 95%CI = 95% 
confidence interval; OLD = Obstructive lung disease; HIV = Human immunodeficiency virus; BMI = Body mass index; pack-yr = Number of 
packs smoked per day * years smokedDrummond et al. BMC Pulmonary Medicine 2010, 10:27
http://www.biomedcentral.com/1471-2466/10/27
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when compared to other HIV risk groups, a confounder
that could impact functional status[42,43]. We also did
not evaluate for underlying cardiac disease as a contribu-
tor to dyspnea. Despite these limitations, the large size of
our cohort, the systematic administration of validated
questionnaires and the use of standardized measures of
lung function allow us to provide a novel and comprehen-
sive study of respiratory symptoms and functional status
in an inner-city IDU population at risk for HIV and OLD.
Conclusions
We show that HIV significantly worsens dyspnea, but has
limited effect on the reported burden of cough, wheezing
and phlegm in individuals of similar OLD status. More-
over, we found that OLD and HIV have an additive detri-
mental effect on dyspnea. HIV is independently
associated with moderate but not severe dyspnea after
controlling for OLD status. The results of this analysis
provide new information which can assist providers man-
aging a population particularly susceptible to the two
important diseases of OLD and HIV.
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